News summary

ProMIS secures brain-targeting technology for Alzheimer’s drug

Source: Longevity Technology • Published: 18 Nov 2026, 13:31

Summarized by Masters of Longevity from Longevity Technology.

ProMIS licensed Ossianix's TXP1 brain-selective shuttle targeting transferrin receptor 1.

ProMIS secures brain-targeting technology for Alzheimer’s drug
Key Takeaways
  • ProMIS licensed TXP1 to enhance CNS delivery of its drug.
  • TXP1 targets transferrin receptor 1 to shuttle therapies into brain.
  • Enhanced delivery may improve drug brain levels but is unproven.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.